Professor Graham Mann

MBBS, PhD, FRACP
Director, The John Curtin School of Medical Research

Professor Graham Mann joined the John Curtin School of Medical Research as its 16th Director in July 2019, bringing a national and international reputation in basic and translational cancer research.

After graduating in Medicine and training in medical oncology in Sydney he studied cell proliferation mechanisms as a graduate student at the Ludwig Institute for Cancer Research, Sydney Branch and as a postdoctoral researcher at the University of Umeå, Sweden. In 1990, having obtained his PhD and FRACP, he established himself at the Westmead campus of Sydney Medical School as a full-time researcher in cancer genetics in partnership with Rick Kefford, focussing on familial melanoma.

Graham helped develop and lead signature genetic epidemiologic projects and resources such as the Australian Melanoma Family Study, the international GenoMEL consortium and the Australian kConFab breast cancer genetics consortium. Among other achievements these studies have identified the genetic bases of melanoma risk in families and the population and the role of sunbeds in melanoma, especially in young adults, and have changed clinical practice and public policy. With a H-index of 55 he has more than 250 primary research publications, cited more than 12,000 times (Scopus).  

In a diverse team of clinical and translational research leaders in melanoma, associated with Melanoma Institute Australia, Graham has held NHMRC Program Grants since 2006, led a new NHMRC Centre of Research Excellence in Melanoma in 2017, and been supported by translational program grants of Cancer Institute NSW. His research has engaged in all aspects of melanoma control, from the genetics of melanoma risk and its environmental and psychological aspects, to the use of molecular markers and targets to improve the diagnosis and treatment of melanoma. From his base in the Westmead Institute he has initiated and co-led the Australian Melanoma Genome Project, the MelCOR Australian Clinical Outcomes Register project, and the ACRF Centre for Excellence in Melanoma Diagnosis (ACEMID) project, last year awarded the triennial $10m ACRF capital grant. At JCSMR he aims to continue these productive collaborations, specifically to exploit the integrated genomics and proteomics of melanoma to develop new biomarkers, drug targets and understanding of cancer.